CTAD 2024 | Novel therapeutics being explored in AD and moving towards combination approaches

Charbel Moussa, MBBS, PhD, Georgetown University Medical Center, Washington, DC, discusses novel therapeutics being explored in the treatment of Alzheimer’s disease (AD). Drugs that induce autophagy and regulate the bioenergetics in the brain, such as tyrosine kinase inhibitors, are being investigated, as well as antibodies that target tau. Dr Moussa mentions that the future may see combinatorial strategies like those used in cancer treatment due to the complexity of AD. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.